Table 4.
Baseline characteristics of rheumatoid arthritis (RA) in remission, RA with low disease activity, RA with moderate to high disease activity and healthy persons in external validation set from cohort 3.
| Characteristics | Healthy subjects | RA in remission | RA with low disease | RA with moderate to high disease |
|---|---|---|---|---|
| (n = 51) | (n = 28) | activity (n = 34) | activity (n = 47) | |
| Female, n (%) | 38 (74.51) | 20 (71.43) | 27 (79.41) | 39 (82.98) |
| Age (years) (mean ± SD) [min, max] | 51.30 ± 14.83 [30, 81] | 48.04 ± 9.82 [31, 72] | 46.88 ± 9.74 [23, 63] | 50.13 ± 12.69 [25, 93] |
| BMI (Kg/m2) (mean ± SD) [min, max] | 21.91 ± 7.07 [17.27, 30.19] | 22.11 ± 4.27 [19.07, 32.11] | 21.01 ± 4.57 [18.61, 30.19] | 22.55 ± 4.23 [19.07, 32.67] |
| Duration of disease (year) (mean ± SD) [min, max] | N/A | 10.17 ± 9.58 [0.50, 30.00] | 11.07 ± 10.50 [0.50, 31.00] | 12.07 ± 10.55 [0.50, 31.00] |
| ESR (mm/h) (mean ± SD) [min, max] | 10.72 ± 6.36 [1.07, 19.81] | 7.79 ± 5.44 [2.00, 20.00] | 19.33 ± 11.84$ [2.00, 20.00] | 45.96 ± 29.81∧∧∧@@@* [2.00, 20.00] |
| CRP (mg/L) (mean ± SD) [min, max] | 4.53 ± 2.57 [0.34, 8.27] | 3.77 ± 1.72 [3.14, 8.90] | 3.69 ± 1.22 [3.14, 7.00] | 14.10 ± 15.70**@@∧ [3.14, 85.10] |
| DAS28 (CRP) | N/A | 1.85 ± 0.48 [1.47, 2.17] | 2.21 ± 0.45 [1.47, 2.80] | 3.98 ± 1.02***@@@ [2.40, 6.37] |
| DAS28 (ESR) | N/A | 1.64 ± 0.64 [0.49, 2.60] | 3.04 ± 0.34 [2.60, 3.98] | 4.66 ± 0.95***@@@ [3.23, 6.82] |
| Rheumatoid factor, n (%) || | N/A | 19 (67.86) | 23 (67.65) | 39 (82.98) |
| ACPA, n (%) || | N/A | 25 (89.29) | 31 (91.18) | 44 (93.62) |
BMI, Body mass index; ESR, Erythrocyte sedimentation rate; CRP, C reactive protein; DAS28, Disease Activity Score with 28-joint counts; N/A, not applicable; ACPA, anti-cyclic citrullinated peptide. || antibody positivity. (*, ‡) significance with moderate to high active RA vs. RA with low disease activity; ($, ′) significance with low active RA vs. RA in remission; (#) significance with RA in remission vs. healthy subjects; (@, !) significance with moderate to high active RA vs. RA in remission; (∧) significance with moderate to high active RA vs. healthy subjects; (&) significance with low active RA vs. healthy subjects. (*, $, #, @, ∧, &) significance by one-way ANOVA with Kruskal-Wallis non-parametric test. (‡,′, !) mean significance by chi-square test. || antibody positivity.